1
|
Koechling W, Plaksin D, Croston GE, Jeppesen JV, Macklon KT, Andersen CY. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect 2017; 6:297-305. [PMID: 28450423 PMCID: PMC5510450 DOI: 10.1530/ec-17-0067] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 04/27/2017] [Indexed: 12/02/2022]
Abstract
Recombinant FSH proteins are important therapeutic agents for the treatment of infertility, including follitropin alfa expressed in Chinese Hamster Ovary (CHO) cells and, more recently, follitropin delta expressed in the human cell line PER.C6. These recombinant FSH proteins have distinct glycosylation, and have distinct pharmacokinetic and pharmacodynamic profiles in women. Comparative experiments demonstrated that follitropin delta and follitropin alfa displayed the same in vitro potency at the human FSH receptor, but varied in their pharmacokinetics in mouse and rat. While follitropin delta clearance from serum depended in part on the hepatic asialoglycoprotein receptor (ASGPR), follitropin alfa clearance was unaffected by ASGPR inhibition in rat or genetic ablation in mice. The distinct properties of follitropin delta and follitropin alfa are likely to contribute to the differing pharmacokinetic and pharmacodynamic profiles observed in women and to influence their efficacy in therapeutic protocols for the treatment of infertility.
Collapse
Affiliation(s)
| | - Daniel Plaksin
- Bio-Technology General Israel LtdFerring Pharmaceuticals, Kiryat Malachi, Israel
| | | | - Janni V Jeppesen
- The Laboratory of Reproductive BiologyThe Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark
| | - Kirsten T Macklon
- The Laboratory of Reproductive BiologyThe Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark
| | - Claus Yding Andersen
- The Laboratory of Reproductive BiologyThe Department of Fertility at The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and The University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
2
|
Peralta O, Bucher D, Angulo C, Castro M, Ratto M, Concha I. Tissue localization of GM-CSF receptor in bovine ovarian follicles and its role on glucose uptake by mural granulosa cells. Anim Reprod Sci 2016; 170:157-69. [DOI: 10.1016/j.anireprosci.2016.04.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 04/25/2016] [Accepted: 04/28/2016] [Indexed: 12/16/2022]
|
3
|
Indirect assessment of neutralizing anti-drug antibodies utilizing pharmacokinetic assay data. J Immunol Methods 2015; 429:28-38. [PMID: 26711311 DOI: 10.1016/j.jim.2015.12.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 12/18/2015] [Accepted: 12/18/2015] [Indexed: 11/23/2022]
Abstract
Neutralizing anti-drug antibodies (NAbs) can adversely impact efficacy and safety of biologic therapeutics. However, current assay formats to detect NAbs are limited in their use during the dosing phase due to interference by circulating drug, resulting in low drug tolerance. To improve the drug tolerance for NAb detection, an alternative approach for indirect NAb (iNAb) assessment was developed and qualified that uses a combination of pharmacokinetic (PK) assays to measure the serum concentrations of free and total drug. It is demonstrated that the ratio of free to total drug concentrations, referred to as F/T ratio, is a novel PK parameter that can indicate neutralizing activity in test samples. The iNAb assessment correctly identified NAb-positive samples with high drug concentrations that led to false negative results in a conventional NAb assay. Moreover, iNAb reliably distinguished between NAbs and non-neutralizing anti-drug antibodies over a wide range of concentrations. A proposal on how to deploy iNAb assessment within a broader immunogenicity testing strategy is presented.
Collapse
|
4
|
Wu Y, Li JJ, Kim HJ, Liu X, Liu W, Akhgar A, Bowen MA, Spitz S, Jiang XR, Roskos LK, White WI. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity. AAPS JOURNAL 2015. [PMID: 26205082 DOI: 10.1208/s12248-015-9798-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Benralizumab is a humanized anti-IL5 receptor α (IL5Rα) monoclonal antibody (mAb) with enhanced (afucosylation) antibody-dependent cell-mediated cytotoxicity (ADCC) function. An ADCC reporter cell-based neutralizing antibody (NAb) assay was developed and characterized to detect NAb against benralizumab in human serum to support the clinical development of benralizumab. The optimal ratio of target cells to effector cells was 3:1. Neither parental benralizumab (fucosylated) nor benralizumab Fab resulted in ADCC activity, confirming the requirement for ADCC activity in the NAb assay. The serum tolerance of the cells was determined to be 2.5%. The cut point derived from normal and asthma serum samples was comparable. The effective range of benralizumab was determined, and 35 ng/mL [80% maximal effective concentration (EC80)] was chosen as the standard concentration to run in the assessment of NAb. An affinity purified goat anti-benralizumab polyclonal idiotype antibody preparation was shown to have NAb since it inhibited ADCC activity in a dose-dependent fashion. The low endogenous concentrations of IL5 and soluble IL5 receptor (sIL5R) did not demonstrate to interfere with the assay. The estimated assay sensitivities at the cut point were 1.02 and 1.10 μg/mL as determined by the surrogate neutralizing goat polyclonal and mouse monoclonal anti-drug antibody (ADA) controls, respectively. The assay can detect NAb (at 2.5 μg/mL) in the presence of 0.78 μg/mL benralizumab. The assay was not susceptible to non-specific matrix effects. This study provides an approach and feasibility of developing an ADCC cell-based NAb assay to support biopharmaceuticals with an ADCC function.
Collapse
Affiliation(s)
- Yuling Wu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA.
| | - Jia J Li
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Hyun Jun Kim
- Analytical Biotechnology Development, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Xu Liu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Weiyi Liu
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Ahmad Akhgar
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Michael A Bowen
- Antibody Development and Protein Engineering, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Susan Spitz
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Xu-Rong Jiang
- Analytical Biotechnology Development, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Lorin K Roskos
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| | - Wendy I White
- Clinical Pharmacology and DMPK, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA
| |
Collapse
|